US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

6.82

+0.930015.79%

Post-market: 6.820.00000.00%19:30 EDT

Volume:173.69K

Turnover:1.12M

Market Cap:147.97M

PE:-2.13

High:6.90

Open:5.91

Low:5.80

Close:5.89

52wk High:17.94

52wk Low:3.35

Shares:21.70M

Float Shares:11.17M

Volume Ratio:1.18

T/O Rate:1.56%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2080

EPS(LYR):-0.7400

ROE:-66.02%

ROA:-40.38%

PB:1.98

PE(LYR):-9.22

Loading ...

Overview Company News Filings

Aardvark Therapeutics Inc - Enters Equity Distribution Agreement With Piper Sandler on March 23, 2026 - SEC Filing

THOMSON REUTERS

Aardvark Therapeutics Inc - May Offer Shares up to $150 Mln Aggregate Offering Price - SEC Filing

THOMSON REUTERS

Aardvark Therapeutics signs equity distribution agreement for up to USD 150 million offering

Aardvark pauses two obesity drug trials as it reviews side effects

Aardvark Therapeutics Files $400 Million Mixed Shelf

MT Newswires Live

Aardvark Therapeutics files $400M mixed securities shelf

Aardvark files USD 400 million shelf registration for common stock and debt securities

Aardvark Therapeutics Inc - May Offer up to $400 Mln in Securities - SEC Filing

THOMSON REUTERS

Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)

Aardvark Therapeutics reports lower-than-expected 2025 net loss

Aardvark Therapeutics Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million

Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate

Benzinga Earnings

Aardvark Therapeutics: Pauses Ard-201 Obesity Program Including Power and Strength Trials; Further Guidance Expected Q2 2026

THOMSON REUTERS

Aardvark Therapeutics: Pauses Phase 3 Hero and Ole Trials for Ard-101 in Pws; Further Guidance Expected Q2 2026

THOMSON REUTERS

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Schall Law Firm Investigates Aardvark Therapeutics for Securities Law Violations

What's Going On With Aardvark Therapeutics Stock On Wednesday?

Benzinga_recent_news

Top Midday Decliners

MT Newswires Live

Aardvark Therapeutics Inc. : Oppenheimer Cuts Target Price to $21 From $35

THOMSON REUTERS

BUZZ-Street View: Aardvark slides after pausing late-stage trial; multiple analysts cut PT

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/AARD/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":6.82,"timestamp":1787342400000,"preClose":5.89,"halted":0,"volume":173693,"hourTrading":{"tag":"盘后","latestPrice":6.82,"preClose":6.82,"latestTime":"19:30 EDT","volume":10,"amount":68.2,"timestamp":1787355006457,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.15789473684210537,"floatShares":11168300,"shares":21696893,"eps":-3.207951,"marketStatus":"Market Closed","change":0.93,"latestTime":"08-21 16:00:00 EDT","open":5.91,"high":6.9,"low":5.8,"amount":1117073.9794318,"amplitude":0.186757,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.207951,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":5.89,"preHourTrading":{"tag":"盘前","latestPrice":6.0144,"preClose":5.89,"latestTime":"09:26 EDT","volume":211,"amount":1267.3644104,"timestamp":1787318775881,"change":0.1244,"changeRate":0.021121,"amplitude":0.036401},"postHourTrading":{"tag":"盘后","latestPrice":6.82,"preClose":6.82,"latestTime":"19:30 EDT","volume":10,"amount":68.2,"timestamp":1787355006457,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1800854433265036,"impliedVol":0.9983,"impliedVolPercentile":0.3878},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":11168300,"roa":"-40.38%","roe":"-66.02%","lyrEps":-0.74,"volumeRatio":1.1800854433265036,"shares":21696893,"dividePrice":0,"high":6.9,"amplitude":0.186757,"preClose":5.89,"low":5.8,"week52Low":3.35,"pbRate":"1.98","week52High":17.94,"institutionHeld":0,"latestPrice":6.82,"eps":-3.207951,"divideRate":0,"volume":173693,"delay":0,"ttmEps":-3.207951,"open":5.91,"prevYearClose":13.125,"prevWeekClose":6.54,"prevMonthClose":6.6,"prevQuarterClose":5.76,"fiveDayClose":6.54,"twentyDayClose":6.32,"sixtyDayClose":3.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"AARD","fiscalQuarterEnding":"2026/06","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-05-07","symbol":"AARD","fiscalQuarterEnding":"2026/03","expectedEps":-0.81,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.99},{"market":"US","date":"2026-03-23","symbol":"AARD","fiscalQuarterEnding":"2025/12","expectedEps":-0.81,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774238400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-08-21","current":-2.125968,"percent":0.843915,"low":-51.17654,"twenty":-9.46418,"median":-6.116088,"eighty":-2.0169,"high":-1.08662,"avg":-7.838471,"sd":8.376805,"marketCap":128901742},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780},{"date":"2026-02-20","current":-5.540193,"twenty":-10.673027,"median":-7.864204,"eighty":-5.92323,"marketCap":270206305},{"date":"2026-02-27","current":-5.580372,"twenty":-10.643124,"median":-7.834638,"eighty":-5.890776,"marketCap":272165900},{"date":"2026-03-06","current":-2.562507,"twenty":-10.619417,"median":-7.684115,"eighty":-5.801764,"marketCap":124978581},{"date":"2026-03-13","current":-2.34822,"twenty":-10.594371,"median":-7.524231,"eighty":-5.747859,"marketCap":114527410},{"date":"2026-03-20","current":-2.187506,"twenty":-10.558368,"median":-7.450451,"eighty":-5.647336,"marketCap":106689032},{"date":"2026-03-27","current":-1.329623,"twenty":-10.505146,"median":-7.272172,"eighty":-5.612515,"marketCap":76574303},{"date":"2026-04-02","current":-1.549332,"twenty":-10.461316,"median":-7.114571,"eighty":-5.565193,"marketCap":89227607},{"date":"2026-04-10","current":-1.477359,"twenty":-10.383939,"median":-7.072594,"eighty":-5.510729,"marketCap":85082559},{"date":"2026-04-17","current":-1.890261,"twenty":-10.268548,"median":-6.92859,"eighty":-5.336927,"marketCap":108862044},{"date":"2026-04-24","current":-2.034209,"twenty":-10.187377,"median":-6.86609,"eighty":-5.089336,"marketCap":117152140},{"date":"2026-05-01","current":-2.056938,"twenty":-10.153251,"median":-6.792493,"eighty":-4.960237,"marketCap":118461102},{"date":"2026-05-08","current":-1.748556,"twenty":-10.125375,"median":-6.716536,"eighty":-4.705593,"marketCap":122169829},{"date":"2026-05-15","current":-2.101422,"twenty":-10.043581,"median":-6.685898,"eighty":-4.518505,"marketCap":146824271},{"date":"2026-05-22","current":-1.408234,"twenty":-9.951007,"median":-6.641483,"eighty":-4.307154,"marketCap":98391896},{"date":"2026-05-29","current":-1.311437,"twenty":-9.918135,"median":-6.60716,"eighty":-4.188404,"marketCap":91628817},{"date":"2026-06-05","current":-1.230253,"twenty":-9.857086,"median":-6.549693,"eighty":-2.633043,"marketCap":85956556},{"date":"2026-06-12","current":-1.136579,"twenty":-9.835549,"median":-6.495974,"eighty":-2.45715,"marketCap":79411641},{"date":"2026-06-18","current":-1.192783,"twenty":-9.824539,"median":-6.468768,"eighty":-2.34822,"marketCap":83338590},{"date":"2026-06-26","current":-1.57997,"twenty":-9.822648,"median":-6.449019,"eighty":-2.187506,"marketCap":110390908},{"date":"2026-07-02","current":-1.754828,"twenty":-9.791341,"median":-6.425331,"eighty":-2.13573,"marketCap":122608083},{"date":"2026-07-10","current":-1.561235,"twenty":-9.726041,"median":-6.368321,"eighty":-2.087243,"marketCap":109081925},{"date":"2026-07-17","current":-1.976523,"twenty":-9.645626,"median":-6.354268,"eighty":-2.066183,"marketCap":138097717},{"date":"2026-07-24","current":-1.995258,"twenty":-9.546006,"median":-6.285834,"eighty":-2.034209,"marketCap":139406700},{"date":"2026-07-31","current":-1.998381,"twenty":-9.523603,"median":-6.216183,"eighty":-2.015866,"marketCap":139624864},{"date":"2026-08-07","current":-2.279403,"twenty":-9.505361,"median":-6.182531,"eighty":-2.029869,"marketCap":159259610},{"date":"2026-08-14","current":-2.007209,"twenty":-9.48453,"median":-6.16129,"eighty":-2.029869,"marketCap":140281862},{"date":"2026-08-21","current":-1.844378,"twenty":-9.46418,"median":-6.116088,"eighty":-2.0169,"marketCap":128901742}],"updateTime":1787456969875},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621789063","title":"Aardvark Therapeutics Inc - Enters Equity Distribution Agreement With Piper Sandler on March 23, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621789063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621789063?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:10","pubTimestamp":1774347027,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C03N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063783","title":"Aardvark Therapeutics Inc - May Offer Shares up to $150 Mln Aggregate Offering Price - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063783?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:10","pubTimestamp":1774347027,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C03N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063186","title":"Aardvark Therapeutics signs equity distribution agreement for up to USD 150 million offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063186","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063186?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:02","pubTimestamp":1774346552,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics entered into an equity distribution agreement with Piper Sandler to sell shares of its common stock from time to time.The program allows sales of up to USD 150.0 million in aggregate offering price under the company’s shelf registration statement.Piper Sandler will receive a 3% commission on the gross sales price per share sold under the agreement.The company is not obligated to sell any shares under the arrangement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5CrwhS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4127","BK4007","AARD","PIPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087042","title":"Aardvark pauses two obesity drug trials as it reviews side effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087042","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087042?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:52","pubTimestamp":1774302726,"startTime":"0","endTime":"0","summary":"March 23  - Aardvark Therapeutics AARD.O said on Monday it has voluntarily paused two mid-stage studies testing its experimental combination treatment for obesity as it reviews side effects associated with one of the drugs.The combination treatment, ARD-201, was being tested to induce weight loss and prevent weight regain among patients who have lost about 15% of body weight on the popular GLP-1 class of drugs, which includes Eli Lilly's LLY.N Zepbound and Novo Nordisk's NOVOb.CO Wegovy.ARD-201 is a combination of Aardvark's experimental drug, ARD-101, and Merck's diabetes drug MRK.N Januvia, chemically known as sitagliptin.ARD-101 is designed to trigger the release of multiple gut-peptide hormones, including GLP-1, to regulate hunger.Last month, the company identified heart-related side effects during safety monitoring of ARD-101 in a healthy-volunteer study. It then paused a late-stage trial testing ARD-101 in patients with a rare genetic disorder called Prader-Willi syndrome.Aardvar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL4N40B1W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069344957.HKD","LU2237443895.HKD","LU0006306889.USD","LU2023250504.SGD","LU0203347892.USD","LU0466842654.USD","LU0942090050.USD","LU0980610538.SGD","LLYX","LU1934455863.HKD","LU2456880835.USD","BK4516","SG9999014898.SGD","SGXZ31699556.SGD","IE00BJJMRZ35.SGD","LU0211331839.USD","LU2089283258.USD","SG9999014542.SGD","SGXZ57979304.SGD","LU1551013342.USD","LU1116320901.HKD","LU1988902786.USD","LU2746668461.USD","LU2236285917.USD","LU0234572021.USD","LU0114720955.EUR","LU1093756325.SGD","SGXZ99366536.SGD","IE00BJJMRX11.SGD","LU2746668974.SGD","LU0648001328.SGD","LU1989772840.SGD","LU2896262040.SGD","SG9999015978.USD","IE0004445015.USD","LU0417517546.SGD","SGXZ51526630.SGD","LU0109391861.USD","LU0820562030.AUD","IE0001KFT4U8.USD","LU0354030438.USD","LU0943347566.SGD","LU0225283273.USD","LU2237443465.HKD","LU2471134523.USD","LU1066051498.USD","LU2471134879.HKD","LU0964807845.USD","IE00BJLML261.HKD","LU2237443978.SGD","LU0354030511.USD","LU2471134796.USD","LU0823434583.USD","LU0256863902.USD","SG9999014914.USD","LU1585245621.USD","LU1934455277.USD","LU0456855351.SGD","LU1989772923.USD","LU0208291251.USD","SG9999013999.USD","LU2237443549.SGD","LU0106261372.USD","IE00BN8TJ469.HKD","LU1941712348.USD","IE00B1XK9C88.USD","LU0265550359.USD","LU0265550946.USD","IE00BBT3K403.USD","LU0477156953.USD","LU0868494708.USD","IE00BN29S564.USD","LU2168564495.EUR","LU2462157665.USD","SG9999001176.SGD","SG9999014906.USD","LU0640476718.USD","IE00BKDWB100.SGD","LU0353189680.USD","LU1267930730.SGD","SG9999017495.SGD","LU0070302665.USD","BK4007","LU2357305700.SGD","IE00B7KXQ091.USD","IE00BK4W5L77.USD","LU1291159041.SGD","LU1035773651.USD","LU2106854487.HKD","LU1868837136.USD","LU1201861249.SGD","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU2552382132.HKD","LU2125154935.USD","LU1712237335.SGD","LU0823434740.USD","LU1804176565.USD","LU1941712264.USD","LU1116320737.USD","BK4533","LU0130517989.USD","LU0198837287.USD","LU1127390331.HKD","LU1145028129.USD","SG9999001176.USD","LU0109394709.USD","SG9999015986.USD","LU2237443382.USD","SG9999014575.USD","SG9999014880.SGD","IE00B4JS1V06.HKD","LU0316494557.USD","LU0203201768.USD","IE00B2B36J28.USD","LU0210536198.USD","LU0471298694.HKD","LU2089984988.USD","LU0820561818.USD","IE00BLSP4239.USD","LU2023251221.USD","LU2491050154.USD","LU1057294990.SGD","LU1162221912.USD","LU2125154778.USD","BK4559","SG9999014567.USD","LU1929549753.HKD","LU1548497426.USD","LU1323610961.USD","LU0323591593.USD","LU1061106388.HKD","LU1629891620.HKD","IE00BJT1NW94.SGD","SG9999018857.SGD","AARD","LU0094547139.USD","LU1035775433.USD","LU2552382215.SGD","IE000M9KFDE8.USD","LU0097036916.USD","LU1720051108.HKD","IE00BWXC8680.SGD","LU0289739699.SGD","LU1720051017.SGD","LU0096364046.USD","BK4585","LU2271345857.HKD","LU1571399168.USD","IE0005OL40V9.USD","BK4581","LU2324357040.USD","LU1814569148.SGD","LU1430594728.SGD","LU1069347547.HKD","LU2023250330.USD","LU0122379950.USD","LU2471134952.CNY","LU0058720904.USD","LLYZ","SG9999015358.SGD","LU0861579265.USD","LU0689472784.USD","LU0079474960.USD","LU0985320562.USD","LU0965509010.AUD","LU2750360641.GBP","LU0203345920.USD","LU1699723380.USD","LU2417539215.USD","LU2237443622.USD","IE0004445239.USD","LU0266013472.USD","LU1868836591.USD","SG9999002224.SGD","IE00B1BXHZ80.USD","ELIS","LU1868837300.USD","LU0256863811.USD","LU0320765489.SGD","LU1093756168.USD","LU2468319806.SGD","LU0098860793.USD","LU2168564222.USD","LU1623119135.USD","LU0820561909.HKD","LU2237438978.USD","LU2211815571.USD","LU0708995401.HKD","LU2168564149.EUR","SG9999015341.SGD","LU2168563687.JPY","BK4534","LU1868836757.USD","LU1037948541.HKD","LU0965508806.USD","IE00BJJMRY28.SGD","LU0787776722.HKD","LU0965509101.SGD","LU0238689110.USD","LU2264538146.SGD","LU0385154629.USD","IE00BK4W5M84.HKD","IE00BFSS7M15.SGD","LU1037948897.HKD","LU2108987350.USD","LU1064131342.USD","LU2461242641.AUD","ELIL","LU2361044949.HKD","LU2361045086.USD","SG9999002232.USD","LU2360106947.USD","LU2552382058.USD","LU2361044865.SGD","LU0889565916.HKD","LU0432979614.USD","LU1934455194.USD","LU2491050071.SGD","LU1066051811.HKD","LU2602419157.SGD","LU0868494617.USD","LU0965509283.SGD","IE00B775H168.HKD","GB00BDT5M118.USD","LU0320765992.SGD","IE0009355771.USD","IE00BKPKM429.USD","LU0203202063.USD","LU1023059063.AUD","LU1366192091.USD","LU2028103732.USD","LU0158827781.USD","LU0882574139.USD","LU2087625088.SGD","LU0353189763.USD","IE0002141913.USD","BK4588","LLII","LU0471298777.SGD","SG9999014559.SGD","LU2112291526.USD","LU2360032135.SGD","LU1974910355.USD","LU0683600562.USD","LU2756315664.SGD","LU2213496289.HKD","LU0061475181.USD","LU1989771016.USD","LU0130102774.USD","LU0823416689.USD","IE00B4R5TH58.HKD","LU2023250843.SGD","SG9999018865.SGD","LU1868836914.USD","SGXZ81514606.USD","LU1983299246.USD","BK4550","LU2265009873.SGD","BK4599","IE00BLSP4452.SGD","LU1066053197.SGD","LU1280957306.USD","LU2063271972.USD","LU2168564065.EUR","LU2491049909.HKD","SG9999015952.SGD","LU1232071149.USD","LU0786609619.USD","LU0320765059.SGD","LU0672654240.SGD","LU2750360997.AUD","LU2111349929.HKD","LU0158827948.USD","LU0882574055.USD","IE00BFSS8Q28.SGD","LU0320765646.SGD","LU1917777945.USD","LU2089284900.SGD","LU2756315318.SGD","LU1066051225.USD","IE00BSNM7G36.USD","LU1551013425.SGD","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621499087","title":"Aardvark Therapeutics Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2621499087","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621499087?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:34","pubTimestamp":1774301669,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics  filed a shelf registration statement on Monday with the US Securities and Exchange Commission for the potential sale of up to $400 million in securities.The filing covers common and preferred stock, debt securities, warrants, rights, units, and depositary shares.Net proceeds will be used for general corporate purposes.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087537","title":"Aardvark Therapeutics files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087537?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:15","pubTimestamp":1774300511,"startTime":"0","endTime":"0","summary":"17:11 EDT Aardvark Therapeutics (AARD) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mov...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087807","title":"Aardvark files USD 400 million shelf registration for common stock and debt securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087807","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087807?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:11","pubTimestamp":1774300305,"startTime":"0","endTime":"0","summary":"Aardvark reported progress around its lead candidate ARD-101, which is being developed for hyperphagia associated with Prader-Willi Syndrome and is positioned as a potential treatment option in an area with limited alternatives.The company said it voluntarily paused enrollment and dosing in the Phase 3 HERO and related open-label extension trials after reversible cardiac observations in a healthy volunteer study, a development that could affect timelines and near-term competitive positioning.Separately, Aardvark filed for a shelf registration covering up to USD 400.0 million of securities, including an at-the-market program of up to USD 150.0 million, which could provide financing flexibility while clinical plans are reviewed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL5SFfRg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621087809","title":"Aardvark Therapeutics Inc - May Offer up to $400 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087809?lang=en_us&edition=fundamental","pubTime":"2026-03-24 05:11","pubTimestamp":1774300276,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0JE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621845600","title":"Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621845600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621845600?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:16","pubTimestamp":1774297012,"startTime":"0","endTime":"0","summary":"As of December 31, 2025, Aardvark had cash, cash equivalents and short-term investments of $110M, compared to $73.7M as of December 31, 2024. Based...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-reports-q4-eps-81c-consensus-83c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-reports-q4-eps-81c-consensus-83c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084871","title":"Aardvark Therapeutics reports lower-than-expected 2025 net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084871","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084871?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:16","pubTimestamp":1774296993,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics reports lower-than-expected 2025 net lossOverviewUS biopharmaceutical firm's 2025 net loss slightly beat analyst expectationsOutlookAardvark expects to provide further guidance o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL1N40B13H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621608125","title":"Aardvark Therapeutics Q4 net loss rises 100% to USD 18 million on R&D expense up 77% to USD 14 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621608125","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621608125?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:07","pubTimestamp":1774296439,"startTime":"0","endTime":"0","summary":"Aardvark published a press release reporting fourth-quarter and full-year 2025 financial results, and said it had USD 110.0 million in cash, cash equivalents and short-term investments as of Dec. 31, 2025.Net loss was USD 17.6 million and net loss per share was USD 0.81 for Q4 2025.R&D expense rose 77.4% to USD 14.3 million in Q4 2025, while G&A expense more than doubled to USD 4.4 million.Management said the Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome and the ARD-201 obesity program were voluntarily paused after reversible cardiac QRS prolongation was observed in healthy-volunteer studies, with further guidance expected in Q2 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL8c54RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4007","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","AARD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621405081","title":"Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621405081","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621405081?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:06","pubTimestamp":1774296385,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.91) by 11.09 percent. This is a 62.5 percent increase over losses of $(2.16) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51419139/aardvark-therapeutics-q4-eps-0-81-beats-0-91-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621558084","title":"Aardvark Therapeutics:  Pauses Ard-201 Obesity Program Including Power and Strength Trials; Further Guidance Expected Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621558084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621558084?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296301,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nPLX25DBD7:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621308455","title":"Aardvark Therapeutics: Pauses Phase 3 Hero and Ole Trials for Ard-101 in Pws; Further Guidance Expected Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621308455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621308455?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nPLX25DBD7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084925","title":"Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084925","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084925?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296300,"startTime":"0","endTime":"0","summary":"Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 AR","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260833/0/en/Aardvark-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","LU0708994859.HKD","PWS","LU0310800379.SGD","LU0128525929.USD","BK4007","LU1267930573.SGD","LU1267930490.SGD","LU0054578231.USD","LU0029874061.USD","LU1892829315.USD","LU0128526141.USD","LU0310799852.SGD","LU0211328371.USD","CCK","LU0211327993.USD","HERO","LU1803068623.USD","LU0029864427.USD","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616355111","title":"Schall Law Firm Investigates Aardvark Therapeutics for Securities Law Violations","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355111","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616355111?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:21","pubTimestamp":1772637694,"startTime":"0","endTime":"0","summary":"The Schall Law Firm has opened an investigation into potential securities law violations by Aardvark Therapeutics Inc. following reports that the company paused a late-stage trial for a rare disease treatment after detecting heart-related side effects in a safety monitoring study involving higher-than-planned doses. Aardvark shares fell more than 47% in after-hours trading on the day of the report.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL8WM2Km:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014039.USD","LU0314104364.USD","LU2095319765.USD","NDAQ","SG9999014021.USD","BK4585","BK4112","LU2210149790.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616552895","title":"What's Going On With Aardvark Therapeutics Stock On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2616552895","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616552895?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:54","pubTimestamp":1772632440,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics pauses Phase 3 HERO trial after cardiac safety observations, sending shares down nearly 61%.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/04/Pipette-Adding-Fluid-To-One-Of-Several-T.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/04/Pipette-Adding-Fluid-To-One-Of-Several-T.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51033235/whats-going-on-with-aardvark-therapeutics-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51033235/whats-going-on-with-aardvark-therapeutics-stock-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4217","AARD","SMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616536317","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2616536317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616536317?lang=en_us&edition=fundamental","pubTime":"2026-03-03 03:31","pubTimestamp":1772479865,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics  said late Friday it paused its phase 3 trial of ARD-101 for hyperphagia in patients with Prader-Willi Syndrome after reversible cardiac observations at above target therapeutic doses were found during routine safety monitoring in a healthy volunteer study.RBC downgraded the stock to sector perform from outperform. Other downgrades include HC Wainwright to neutral from buy.Shares sank 56% Monday, with intraday trading volume of over 2.24 million against a daily average of about 191,000.uniQure  shares tumbled 32% after the US Food and Drug Administration said data from the company's phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.More than 13.7 million shares traded intraday, compared with a daily average of about 2.64 million.Price: 5.46, Change: -7.03, Percent Change: -56.29","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","LU0889565916.HKD","BK4139","AARD","QURE","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616338330","title":"Aardvark Therapeutics Inc. : Oppenheimer Cuts Target Price to $21 From $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2616338330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616338330?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:37","pubTimestamp":1772458648,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nAZN4SJ5BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616337074","title":"BUZZ-Street View: Aardvark slides after pausing late-stage trial; multiple analysts cut PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2616337074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616337074?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:32","pubTimestamp":1772458379,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Aardvark slides after pausing late-stage trial; multiple analysts cut PTMarch 2 (Reuters) - ** Aardvark Therapeutics AARD.O on Friday voluntarily paused a late-stage trial testing it","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL4N3ZQ151:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":108,"code":"91000000","status":"200"}]}}